ScreenerHero

ZBIO Zenas BioPharma, Inc.

NAS · US · Healthcare · Biotechnology · zenasbio.com
26.24USD-6.88%Mkt Cap: 1.71B $P/E: —

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclona…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap1.71B USD
Enterprise Value1.41B USD
Revenue (TTM)1.00M USD
Gross Profit-212.47M USD
Net Income (TTM)-377.74M USD
Revenue/Share0.02 USD
Last Price26.24 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees167
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.78
PEG—
EV/EBITDA-5.15
EV/Revenue1410.60
P/S1755.86
P/B6.90
EPS (TTM)-9.63
EPS (Forward)-4.66
52W Range
13.5041% of range44.60
52W High44.60 USD
52W Low13.50 USD
Profitability
Gross Margin0.00%
Oper. Margin-7765.90%
EBITDA Margin0.00%
Profit Margin-3777.37%
ROE-156.00%
ROA-98.46%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-172.33M USD
CapEx (TTM)35.02M USD
FCF Margin-21139.16%
FCF Yield-12.36%
Net Debt-345.27M USD
Net Debt/EBITDA1.26
Balance Sheet
Debt/Equity0.01
Current Ratio9.93
Quick Ratio9.78
Book Value/Sh3.90 USD
Cash/Share9.87 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)47.88 USD
Upside (mean)+82.5%
Target Range32.00 USD – 59.00 USD
32.00+82.5% to mean59.00
# Analysts8
Ownership
Shares Out.65.18M
Float45.02M
Insiders19.75%
Institutions101.52%
Short Interest
Short Ratio17.0d
Short % Float26.74%
Short % Out.18.21%
Shares Short11.87M
Short (prev mo.)11.66M
Technical
SMA 5031.17 (-15.8%)
SMA 20025.23 (+4.0%)
Beta-0.88
S&P 52W Chg16.45%
Avg Vol (30d)690.98K
Avg Vol (10d)789.51K
Technical Indicators
RSI (14)37.3
MACD-1.1742
MACD Signal-0.9514
MACD Hist.-0.2228
BB Upper33.88 USD
BB Middle29.28 USD
BB Lower24.69 USD
BB Width31.41%
ATR (14)1.959 USD
Vol Ratio (20d)0.73x